Franziska Thaler

Neuroimmunologist, clinician scientist investigating the immunobiology of autoimmune encephalitis

[Neurology Today @NeurologyToday]

Via @GreenJournal: Researchers have found Class IV evidence of an association between rituximab and a lower hazard to relapse in patients with autoimmune encephalitis: https://t.co/JR8esZgUHY

#NeuroTwitter @AANMember

[Carsten Finke @carstenfinke]

In NMDA receptor #encephalitis, patients with persistent CSF NMDAR-Abs at 12 months were more likely to have subsequent relapses and a poor long-term outcome

[Negaar /nɛˈɡɑr/ Molazadeh٫ M.D. @NegarMowlazadeh]

Don’t miss this excellent updated review: “Autoimmune encephalitis: recent clinical and biological advances”
⁦@ANG_Oxford⁩ https://t.co/bDDfJPoe5t

[Brain @Brain1878]

Cytotoxic T cells and plasma cells dominate early in temporal lobe epilepsy with GAD antibodies.

New scientific commentary by Franziska Thaler & Edgar Meinl https://t.co/HKTdMHPmUL

[Brain @Brain1878]

Steinke et al. develop and validate a construct that neutralizes autoantibodies from patients with NMDAR encephalitis, and prevents receptor internalization and memory deficits in a mouse model. https://t.co/q7ODQHPpxx

[Adrian Budhram @adrianbudhram1]

Thanks @AAN @GreenJournal N2 for publishing our experience using prolonged corticosteroids for anti-LGI1 encephalitis. Examining the impact of acute immunotherapy regimen on need for maintenance immunotherapy may help optimize our treatment approach.

https://t.co/rKf9YWdTkN

[KawakamiLab @KawakamiLab]

Congratulations to @LabMader on their new publication! 🥳It was a pleasure to contribute.
Take a look at the pathomechanisms of MOG-antibody-associated disease: https://t.co/Flb2mLtHLj

[Franziska Thaler @ThalerLab]

Happy to share our new manuscript. Many thanks to all co-authors for this great collaboration!
@kathieisenhut, @edubeltran_lab, @LabMader, @Ker_Lab, @LabMeinl, @INIM_Munich https://t.co/nOoeHHBQsm

[Brain @Brain1878]

In a large cohort of patients with anti-IgLON5 disease, Grüter et al. reveal early inflammatory CSF changes, and association of HLA-DRB1*10:01 with higher autoantibody titre, consistent with a primary autoimmune nature of the disease. https://t.co/GoOhcYQM1R

[Neurology Journal @GreenJournal]

Study data support the hypothesis that the accumulation of GAD65-specific B cells and plasma cells in the CSF is an important feature of early disease stages of GAD65-Ab spectrum disorders, such as stiff-person syndrome and cerebellar ataxia. Learn more: https://t.co/Gqoymei7pV

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

What happened to #neurological #autoantibody detection rates around the pandemic? We compared 2019 Vs 2020, across the 5 commonest cell surface Abs, and only saw a fall in LGI1 rates. The drop was marked around March-June - the time of the UK lockdown. https://t.co/RkrwjYUTKx

[MaderLab @LabMader]

Check out our new manuscript. Many thanks for this great collaboration: @Samanth68485267, Eva Oswald, Hoi Kiu Wong, @AtayVural, Vuslat Yilmaz, Erdem Tüzün, Recai Türkoğlu, Tobias Straub, Ingrid Meinl, @ThalerLab, Tania Kümpfel @LabMeinl,@LabMader

[Brain @Brain1878]

Tröscher et al. show that in patients with GAD65 antibody-associated temporal lobe epilepsy, cytotoxic T cells attack and kill neurons and are responsible for the early neuronal loss. https://t.co/9buT7VWUdd